PerkinElmer's Horizon Discovery Says Extends Gene Modulation Portfolio With 'Industry First' Synthetic Single Guide RNA And Patent Pending dCas9 Repressor For CRISPR Interface
PerkinElmer's Horizon Discovery Says Extends Gene Modulation Portfolio With 'Industry First' Synthetic Single Guide RNA And Patent Pending dCas9 Repressor For CRISPR Interface
Horizon Discovery Extends Gene Modulation Portfolio with Industry First Synthetic Single Guide RNA and Patent Pending dCas9 Repressor for CRISPR Interference
Horizon Discovery推出業界首個合成單引導RNA和正在申請專利的用於CRISPR幹擾的dCas9抑制物，擴大了基因調製產品組合
CRISPRi Innovations Provide Expanded Experimental Options and Flexibility For Researchers Facilitating Disease & Drug Research
CRISPRi創新為促進疾病和藥物研究的研究人員提供了更多的實驗選擇和靈活性
Horizon Discovery, a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its gene editing and modulation portfolio is expanding to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi). CRISPRi enables scientists to better understand the biological pathways, processes and pathologies of disease by repressing genes at the transcriptional level, ultimately leading to new therapeutic approaches.
地平線發現號，一部PerkinElmer公司*(紐約證券交易所：PKI)公司今天宣佈，其基因編輯和調製產品組合正在擴大，包括一系列新的CRISPR調製(CRISPRmod)試劑，用於CRISPR幹擾(CRISPRi)。CRISPRi使科學家能夠通過在轉錄水準上抑制基因，更好地瞭解疾病的生物途徑、過程和病理，最終導致新的治療方法。
The new reagents include the first-ever commercially available synthetic single guide RNAs for CRISPRi, as well as a patent-pending, dCas9-SALL1-SDS3 repressor available in mRNA and lentiviral formats. With these new technologies, researchers will have the flexibility to repress genes in almost all cell lines, over any length of time, and at any scale from single gene readouts to high-throughput studies.
新試劑包括有史以來第一個商業化的試劑。針對CRISPRI的合成單導RNA，以及正在申請專利的dCas9-SALL1-SDS3抑制子。mrna和慢病毒各種格式。有了這些新技術，研究人員將可以靈活地抑制幾乎所有細胞系中的基因，在任何時間段，從單基因讀出到高通量研究的任何規模。
The novel dCas9-SALL1-SDS3 repressor was developed following extensive research and has shown more robust and consistent gene modulation over a longer course of time compared to current-generation CRISPRi products.
新的dCas9-SALL1-SDS3抑制子是經過廣泛研究開發的，與當前一代的CRISPRi產品相比，它在更長的時間內顯示出更強大和一致的基因調控。
Alan Fletcher, SVP Life Sciences at PerkinElmer said, "CRISPRi is gene knockdown, not knockout. It's CRISPR without the cut, so it offers a temporary and nuanced approach which is ideal for researchers looking to mimic cellular effects of small molecule drugs or do multiplexed gene interrogation. By offering these new reagents, in addition to our existing CRISPR options, we're primed to aid researchers in achieving even more exciting breakthroughs in the years ahead."
PerkinElmer生命科學高級副總裁艾倫·弗萊徹說：“CRISPRi是基因剔除，而不是敲除。它是一種沒有切割的CRISPR，因此它提供了一種臨時和細微差別的方法，對於希望類比小分子藥物的細胞效應或進行多路基因詢問的研究人員來說，這是理想的。通過提供這些新試劑，加上我們現有的CRISPR選項，我們準備在未來幾年幫助研究人員取得更令人興奮的突破。”
Horizon Discovery's Dharmacon technology, with its patented siRNA tools, has been the market leader in gene modulation for more than 20 years. Since the discovery of CRISPR gene editing tools, Horizon has been on the forefront offering guide and nuclease products to enable precision DIY CRISPR knockout and knock-in as well as custom screening and cell line production services. CRISPRmod CRISPRi continues the tradition of innovation by developing novel CRISPR-based transcriptional gene modulation reagents. Portfolio-wide, Horizon helps researchers answer fundamental biological questions leading to therapeutic advancements.
Horizon Discovery的達哈納康技術憑藉其獲得專利的siRNA工具，20多年來一直是基因調製領域的市場領先者。自從發現CRISPR基因編輯工具以來，Horizon一直走在前列，提供指南和核酸酵素產品，實現精確的DIY CRISPR基因剔除和敲入，以及定製篩選和細胞系生產服務。CRISPRmod CRISPRi通過開發基於CRISPR的新型轉錄基因調製試劑，延續了創新的傳統。在整個投資組合中，Horizon幫助研究人員回答導致治療進步的基本生物學問題。
For further information on Horizon Discovery's CRISPRi technology, please visit: https://horizondiscovery.com/en/applications/crisprmod/crispri.
有關Horizon Discovery公司CRISPRi技術的更多資訊，請訪問：Https://horizondiscovery.com/en/applications/crisprmod/crispri。
About PerkinElmer
關於PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at https://www.perkinelmer.com/.
PerkinElmer使科學家、研究人員和臨床醫生能夠解決他們在科學和醫療保健領域面臨的最嚴峻挑戰。我們的使命是致力於為更健康的世界創新，我們提供獨特的解決方案，服務於診斷、生命科學、食品和應用市場。我們與客戶建立戰略合作夥伴關係，以便在深厚的市場知識和技術專長的支持下，更早、更準確地洞察情況。我們在全球擁有約14,000名員工的敬業團隊熱忱地幫助客戶創建更健康的家庭，提高生活品質，並維持全球人民的福祉和長壽。該公司2020年的收入約為38億美元，服務於190個國家和地區的客戶，是S指數的成分股。欲瞭解更多資訊，請撥打電話1-877-PKI-NYSE，或登錄：Https://www.perkinelmer.com/。
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005565/en/
在Business Wire.com上查看源代碼版本：Https://www.businesswire.com/news/home/20210329005565/en/
譯文內容由第三人軟體翻譯。